Eli Lilly (NYSE: LLY) Wins First European Approval For Oral Weight-Loss Pill Foundayo In UK

Foundayo: The new weight loss pill approved for the UK

Foundayo has been approved for treating weight loss as well as type 2 diabetes

Eli Lilly (NYSE: LLY) Wins First European Approval For Oral Weight-Loss Pill Foundayo In UK

Britain’s medicines regulator authorized Eli Lilly and Company’s (NYSE: LLY) oral GLP-1 drug orforglipron on August 10, making the UK the first European country to approve the pill. The UK’s Medicines and Healthcare Products Regulatory Agency cleared orforglipron, marketed under the brand name Foundayo, for weight loss and maintenance in obese adults and select overweight individuals with weight-related health conditions. The approval also cover…